Abstract:Background: Clear cell renal cell carcinoma is the most common and fatal form of kidney cancer, accounting for 80% of new cases. Although it has been reported that GTSE1 is highly expressed in a variety of tumors and associated with malignant progression and poor clinical prognosis, its clinical significance, correlations with immune cell infiltration and biological function in ccRCC are still poorly understood. Methods: The gene expression, clinicopathological features, and clinical significance of GTSE1 were analyzed using multiple databases, including TCGA, GEO, TIMER, and UALCAN Kaplan–Meier survival analysis, gene set enrichment analysis gene ontology enrichment Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed. Tumor-infiltrating immune cells and immunomodulators were extracted and analyzed using TCGA-KIRC profiles. Protein‒protein interactions were built using the STRING website. The protein level of GTSE1 in ccRCC patients was detected by immunohistochemistry using a ccRCC tissue chip. Finally, MTT assays, colony-formation assays, cell flow cytometry analyses, EdU-staining assays, wound-healing assays, and transwell migration and invasion assays were conducted to assess the biological function of GTSE1 in vitro . Results: GTSE1 was overexpressed in ccRCC tissues and cells, and GTSE1 overexpression was associated with adverse clinical-pathological factors and poor clinical prognosis. Meanwhile, the functional enrichment analysis indicated that GTSE1 and its coexpressed genes were mainly related to the cell cycle, DNA replication, and immunoreaction, such as T-cell activation and innate immune response, through multiple signaling pathways, including the P53 signaling pathway and T-cell receptor signaling pathway. Furthermore, we observed a significant relationship between GTSE1 expression and the levels of infiltrating immune cells in ccRCC. Biological functional studies demonstrated that GTSE1 could promote the malignant progression of ccRCC by promoting cell proliferation, cell cycle transition, migration, and invasion capacity and decreasing the sensitivity of ccRCC cells to cisplatin. Conclusion: Our results indicate that GTSE1, serving as a potential oncogene, can promote malignant progression and cisplatin resistance in ccRCC. Additionally, high GTSE1 expression contributes to an increased level of immune cell infiltration and is associated with a worse prognosis, providing a potential target for tumor therapy in ccRCC.

Overexpression of G2 and S Phase-Expressed-1 Contributes to Cell Proliferation, Migration, and Invasion Via Regulating P53/foxm1/ccnb1 Pathway and Predicts Poor Prognosis in Bladder Cancer.

GSE1 Predicts Poor Survival Outcome in Gastric Cancer Patients by SLC7A5 Enhancement of Tumor Growth and Metastasis.

GTSE1 promotes tumor growth and metastasis by attenuating of KLF4 expression in clear cell renal cell carcinoma

High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis

GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis

GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner

G2 and S phase‐expressed‐1 acts as a putative tumor promoter in cervical cancer by enhancing Wnt/β‐catenin signaling via modulation of GSK‐3β

Pan-cancer analyses reveal GTSE1 as a biomarker for the immunosuppressive tumor microenvironment.

Silencing GTSE-1 Expression Inhibits Proliferation and Invasion of Hepatocellular Carcinoma Cells

Clinical significance of GTSE 1 expression in colorectal carcinoma

Integrated transcriptome analysis of CSE1L regarding poor prognosis and immune infiltration in bladder urothelial carcinoma and experimental verification

Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway

Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer.

High G2 and S-phase Expressed 1 Expression Promotes Acral Melanoma Progression and Correlates with Poor Clinical Prognosis.

GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma

Up-regulation of GTSE1 lacks a relationship with clinical data in lung cancer.

UBE2T Silencing Suppresses Proliferation and Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells.

Overexpression of FOXS1 in gastric cancer cell lines inhibits proliferation, metastasis, and epithelial‐mesenchymal transition of tumor through downregulating wnt/β‐catenin pathway

GINS1 promotes the initiation and progression of bladder cancer by activating the AKT/mTOR/c-Myc signaling pathway

BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial–Mesenchymal Transition

GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer